Browse News
Filter News
Found 162 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
4/16/2024
Provectus Biopharmaceuticals, Inc. today announced additions to its executive leadership team, reflecting Provectus's dedication to enhancing shareholder value.
-
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
3/25/2024
ProKidney Corp. announced two recent strategic appointments enhancing the leadership team’s expertise in clinical operations and technical operations, positioning the Company for completion of its Phase 3 program and future commercialization.
-
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
3/14/2024
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film and findings from the FDA Type C meeting.
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
3/14/2024
Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.
-
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
3/11/2024
FibroGen, Inc. announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
-
How Upcoming KRAS Inhibitors are Expected to Shape the Future Oncology Market Landscape?
2/26/2024
KRAS stands out as the most commonly altered among the trio of RAS genes, with NRAS and HRAS following suit. The human KRAS gene resides on chromosome 12p12.1 and comprises six exons, primarily positioned in exon 1 at sites 12 and 13, though occasionally found in codons 61, 63, 117, 119, and 146.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
2/15/2024
Aquestive Therapeutics, Inc. announced a poster presentation highlighting the positive pharmacokinetic and pharmacodynamic data from two completed clinical studies for Anaphylm will be presented at the American Academy of Allergy, Asthma, and Immunology 2024 annual meeting, which will take place February 23-26 in Washington, D.C.
-
Grab an umbrella, it's raining IPOs!
1/24/2024
This week, Lori, Greg and Tyler discuss the first surge of IPO activity this year plus gene therapy pricing, -
Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations
1/4/2024
Ashvattha Therapeutics announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations.
-
BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.
-
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
12/18/2023
Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants.”
-
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
12/13/2023
Rain Oncology Inc., announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share.
-
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
12/5/2023
Aquestive Therapeutics, Inc. today announced that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm is the Company’s orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
-
Precision Oncology Market Size is Valued to Soar USD 258.35 Billion by 2032
12/5/2023
The global precision oncology market size was estimated to grow from USD 100.06 billion in 2022 and is valued to soar USD 258.35 billion by 2032, at an expanding CAGR of 9.9% between 2023 and 2032.
-
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
11/15/2023
Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) in combination with standard of care immune checkpoint blockade (CB) for the treatment of advanced cutaneous melanoma ( NCT02557321 ).
-
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
11/13/2023
Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
11/10/2023
Aquestive Therapeutics, Inc. today announced that two posters recapping the positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which will be held from November 9-13 in Anaheim, California.
-
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Rain Oncology Inc. reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.